Lunit INSIGHT MMG: AI-Powered Software for 2D Mammograms

A globally trusted AI software that delivers smarter, earlier breast cancer detection.

Logo 1
Logo 2
This product is not available for sale or distribution in all countries.
Detect with confidence

Detect with confidence

Empower radiologists with AI that enhances insight by providing malignancy likelihood scores and classifying lesions.
Support faster reading

Support faster reading

Interpret images faster and reduce cognitive load by highlighting key areas of interest.
Improve patient experience

Improve patient experience

Help reduce callbacks and anxiety by increasing clarity and consistency in interpretation.

Seamless AI Support for Breast Cancer Detection

Lunit INSIGHT MMG (2D) mammography software supports earlier breast cancer detection, especially in dense breasts and interval cancers.

Designed for streamlined PACS and viewer integration, it delivers AI-driven insights during image review. This shortens reading time, supports single- and double-reading workflows, and helps address the shortage of breast imaging specialists in high-volume settings.

Seamless AI Support for Breast Cancer Detection
Bar chart showing AI mammography software achieving 18% higher accuracy in dense breasts and 8% higher accuracy overall compared to radiologists.

Improved screening accuracy, especially in dense breasts

Lunit INSIGHT MMG has an 18% higher accuracy in extremely dense breasts and an 8% higher accuracy in all breast density categories, enhancing detection across tissue types*.

*Kwon, Mr., Chang, Y., Ham, SY. et al. Screening mammography performance according to breast density: a comparison between radiologists versus standalone intelligence detection. Breast Cancer Res 26, 68 (2024).

Earlier diagnosis in overlooked cases

In a retrospective analysis, Lunit INSIGHT MMG correctly identified suspicious findings in a mammogram from 2020 that was originally overlooked. The patient was not diagnosed until 2022—highlighting the potential of AI mammogram reading tools to support earlier diagnosis.

Up to 40% of breast cancer cases* can be diagnosed earlier with AI support.

*Nanaa et al. Accuracy of an Artificial Intelligence System for Interval Breast Cancer Detection at Screening Mammography. Radiology 2024.

Comparison of mammograms showing lesion missed by radiologist but detected by AI mammography software, leading to earlier cancer diagnosis.

Fewer false positives and callbacks

By improving specificity*, Lunit INSIGHT MMG reduces false positives and unnecessary callbacks. This supports more confident interpretation, lowers patient anxiety, and reduces follow-up burden on clinical teams.

*Kwon, Mr., Chang, Y., Ham, SY. et al. Screening mammography performance according to breast density: a comparison between radiologists versus standalone intelligence detection. Breast Cancer Res 26, 68 (2024).

Mammogram comparison showing AI mammography software reducing false positives and follow-up callbacks by confirming absence of cancer.

Testimonials

Lunit INSIGHT MMG (2D)

“They tell me: you’re finding the smallest cancers we didn’t see before. It’s making a real difference.”

“With AI, we’re not just reading images faster – we’re changing lives.”

Dr. Megha Gupta, MD
Dr. Megha Gupta, MD
Breast and Body Radiologist, Sol Radiology, Victorville, California
Lunit INSIGHT MMG (2D)

“New South Wales is proud to lead the way in the introduction of cutting-edge technology to ensure the sustainability of the life-saving BreastScreen NSW program.”

Ryan Park, Minister for Health
Ryan Park, Minister for Health
NSW Government
Detect Breast Cancer with Greater Clarity and Confidence

Detect Breast Cancer with Greater Clarity and Confidence

See how Lunit INSIGHT MMG improves accuracy, reduces callbacks, and supports radiologists with fast, reliable results at every step of the screening workflow.

Frequently Asked Questions

Does a higher score mean a worse prognosis?

No. The AI mammography software is trained to predict the likelihood that a lesion is cancerous, not its severity, clinical implications, or treatment outcome. While invasive cancers may receive higher scores than noninvasive ones, that is not always the case. If the AI is confident that a malignant lesion exists, it assigns the score accordingly, regardless of subtype.

Note: The scale is not linear (e.g., a score of 90 is not three times more suspicious than a score of 30).